Feno: Guiding personalized copd management.

Pierre Lefevre*

Department of Pulmonology, University of Paris, France

Introduction

Research has consistently explored the utility of fractional exhaled nitric oxide (FeNO) as a non-invasive biomarker for detecting eosinophilic airway inflammation in patients diagnosed with stable Chronic Obstructive Pulmonary Disease (COPD). The findings from various studies suggest that FeNO levels show a significant correlation with sputum eosinophil counts, particularly in individuals who experience frequent exacerbations. This correlation strongly indicates FeNO's substantial potential for effectively guiding personalized anti-inflammatory therapy strategies [1].

In a broad scope, systematic reviews and meta-analyses have meticulously synthesized comprehensive evidence regarding FeNO levels within COPD patient populations. These analyses commonly conclude that FeNO values are generally observed to be lower in COPD patients when compared to healthy control groups. However, it's a nuanced picture, as FeNO levels can indeed be notably elevated in specific COPD phenotypes, particularly in those presenting with eosinophilic inflammation or a history of frequent exacerbations, thereby highlighting its considerable diagnostic potential in clinical practice [2].

Further studies have delved into investigating the intricate correlation between FeNO levels and various crucial clinical characteristics observed in stable COPD patients. A clear association has been established, revealing that FeNO values are linked with important factors such as a patient's exacerbation history and key lung function parameters. This connection suggests that FeNO could serve as a valuable tool, aiding clinicians in more precisely phenotyping COPD and more accurately assessing the overall severity of the disease in individual patients [3].

Several review articles have actively discussed the evolving role of exhaled nitric oxide as a potential and highly promising biomarker in COPD. These reviews emphasize its distinct utility in effectively differentiating between various complex COPD phenotypes, with a particular focus on identifying eosinophilic inflammation. This distinction carries significant implications for developing and implementing personalized therapeutic strategies, as FeNO's role in guiding targeted anti-inflammatory treatments is increasingly recognized as central to effective patient management [4].

Beyond isolated markers, meta-analyses have rigorously investigated the direct relationship between peripheral blood eosinophil counts and FeNO levels in patients afflicted with COPD. A significant association has been consistently found, strongly suggesting that both markers can be utilized synergistically. This combined approach allows for a more comprehensive identification and characterization of eosinophilic airway inflammation in COPD, a crucial step that directly impacts and informs subsequent treatment decisions for patients [5].

Systematic reviews and meta-analyses have specifically undertaken the task of evaluating the diagnostic accuracy of FeNO in precisely identifying eosinophilic airway inflammation within the COPD patient cohort. The cumulative findings from these evaluations robustly support FeNO's position as a highly useful and non-invasive tool for this specific diagnostic purpose. This capability opens doors for potentially guiding personalized anti-inflammatory therapies effectively in a real-world clinical setting, improving patient outcomes [6].

Other studies have meticulously investigated the intriguing link between FeNO levels and the presence of small airway dysfunction in stable COPD patients. These investigations have consistently revealed a notable association, where higher FeNO concentrations are linked with worse small airway function. This compelling finding suggests that FeNO might not only broadly reflect overall airway inflammation but could also specifically indicate inflammatory processes occurring within the peripheral airways, thereby contributing to the intricate progression of the disease [7].

Prospective cohort studies have taken an important step forward by examining the predictive value of FeNO levels for various critical clinical outcomes in COPD patients. It has been observed that persistently higher FeNO levels are significantly associated with an increased risk of experiencing future exacerbations and a more pronounced decline in lung function over time. This crucial predictive capability firmly positions FeNO as a valuable prognostic biomarker, essential for effective disease management and patient care planning [8].

Research has also delved into the complex relationship between FeNO and systemic inflammatory markers prevalent in COPD pa-

***Correspondence to:** Pierre Lefevre, Department of Pulmonology, University of Paris, France. E-mail: pierre.lefevre@pulmo-clinique.fr

Received: 01-Jul-2025, Manuscript No. AAJPCR-25-219; **Editor assigned:** 03-Jul-2025, Pre QC No. AAJPCR-25-219 *(PQ)*; **Reviewed:** 23-Jul-2025, QC No. AAJPCR-25-219; **Revised:** 01-Aug-2025, Manuscript No. AAJPCR-25-219 *(R)*; **Published:** 12-Aug-2025, DOI: 10.35841/aajpcr-8.4.219

Citation: Lefevre P. Feno: Guiding personalized copd management. J Pulmonol Clin Res. 2025;08(04):219.

tients. This exploration uncovered meaningful associations between FeNO levels and circulating inflammatory cytokines, indicating a broader role for this biomarker. This suggests that FeNO might reflect not merely local airway inflammation but also contribute significantly to understanding the pervasive systemic inflammatory burden that is characteristic of COPD, offering insights into its overall pathology [9].

Finally, further research has explored the critical prognostic utility of FeNO specifically in COPD patients who are currently receiving triple therapy. These investigations have indicated that baseline FeNO levels hold the potential to reliably predict future exacerbation risk and, importantly, the patient's response to the administered treatment regimen. This highlights FeNO's significant role in refining individualized treatment approaches and ultimately optimizing therapeutic outcomes for this specific patient group, moving towards more precision medicine [10].

Conclusion

Fractional exhaled nitric oxide (FeNO) is increasingly recognized as a crucial non-invasive biomarker in Chronic Obstructive Pulmonary Disease (COPD). It effectively detects eosinophilic airway inflammation, showing correlations with sputum eosinophil counts and indicating potential for guiding anti-inflammatory treatments. While typically lower in COPD patients than healthy individuals, FeNO levels rise in specific phenotypes, particularly those with eosinophilic inflammation or frequent exacerbations, underscoring its diagnostic utility. This biomarker also associates with critical clinical characteristics like exacerbation history and lung function, supporting its role in phenotyping COPD and assessing disease severity. Here's the thing, FeNO is instrumental in differentiating various COPD phenotypes, especially eosinophilic inflammation, which allows for more personalized therapeutic strategies. A significant relationship between peripheral blood eosinophil counts and FeNO levels has been observed, suggesting these markers can synergistically identify and characterize eosinophilic airway inflammation to inform treatment decisions. Beyond diagnosis, FeNO offers prognostic value; higher levels are linked to an increased risk of future exacerbations and a decline in lung function, positioning it as an important tool for disease management. Studies also show FeNO's association with small airway dysfunction and systemic inflammatory markers, indicating it reflects not just local airway inflammation but also broader inflammatory processes. What this really means is, FeNO has utility in predicting treatment response, particularly in patients on triple therapy, helping refine individualized care. This comprehensive understanding of FeNO's multifaceted role is vital for optimizing COPD diagnosis, phenotyping, prognosis, and tailored therapeutic interventions.

References

1. Yoshinori T, Satoshi T, *Michiaki H. Exhaled nitric oxide as a biomarker for eosinophilic airway inflammation in COPD. Respir Investig.* 2020;58:28-34.
2. Shuang Z, Yang Y, Rui H. Fractional exhaled nitric oxide in COPD: a systematic review and meta-analysis. *Front Med* (Lausanne). 2021;8:646964.
3. Zhiyu L, Yan Z, *Yan F. Relationship between fractional exhaled nitric oxide and clinical characteristics of patients with stable chronic obstructive pulmonary disease. J Int Med Res.* 2022;50(11):03000605221139418.
4. Jorge M, Sara A, Ana B. Exhaled Nitric Oxide in COPD: *Potential Biomarker for Different Phenotypes and Therapeutic Targets. Int J Mol Sci.* 2021;22(10):5462.
5. Jianping D, Zhichao L, Jing Z. Peripheral eosinophil count and fractional exhaled nitric oxide in patients with COPD: a systematic review and meta-analysis. *Ann Palliat Med.* 2020;9(4):1928-1937.
6. Meng L, Yuancai C, Bin W. Fractional exhaled nitric oxide for identifying eosinophilic airway inflammation in patients with COPD: a systematic review and meta-analysis. *Sci Rep.* 2021;11(1):10600.
7. Nan S, Zijing W, *Yan F. Relationship between fractional exhaled nitric oxide and small airway dysfunction in patients with stable COPD. Int J Chron Obstruct Pulmon Dis.* 2023;18:1055-1065.
8. Satoshi T, Yoshinori T, Michiaki H. Exhaled Nitric Oxide and Clinical Outcomes in COPD: *A Prospective Cohort Study. Int J Chron Obstruct Pulmon Dis.* 2024;19:227-234.
9. Jing Z, Yan L, *Lei M. Fractional exhaled nitric oxide and systemic inflammation in chronic obstructive pulmonary disease. J Int Med Res.* 2020;48(11):0300060520970634.
10. Lihua Z, Youmin Z, *Hong Z. Prognostic value of fractional exhaled nitric oxide in patients with chronic obstructive pulmonary disease treated with triple therapy. BMC Pulm Med.* 2021;21(1):279.

Citation: *Lefevre P. Feno: Guiding personalized copd management. J Pulmonol Clin Res. 2025;08(04):219.*